177Lu-DOTA-NOC

177Lu-DOTA-NOC (Lutetium (177Lu) DOTA-NOC) is a therapeutic radiopharmaceutical developed for peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR)-expressing tumors, particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and rare subtypes like VIPomas. It consists of the beta-emitting radionuclide lutetium-177 (177Lu) complexed via the macrocyclic chelator DOTA to the somatostatin analog NOC ([DOTA0-D-Phe1-1-Nal3]-octreotide). Unlike SSTR2-selective analogs like DOTA-TATE, DOTA-NOC exhibits a broader binding profile with high affinity for somatostatin receptor subtypes 2, 3, and 5 (SSTR2, SSTR3, and SSTR5). Upon binding to these receptors on tumor cells, the radioconjugate is internalized, delivering localized cytotoxic beta radiation that induces DNA double-strand breaks and cell death. 177Lu-DOTA-NOC has been evaluated in investigator-initiated Phase 1/2 clinical trials, demonstrating efficacy and a manageable safety profile.

Other names

[177Lu]-DOTA-NOC[177Lu]Lu-DOTA-1-Nal3-octreotide[177Lu]Lu-DOTA-NOC177Lu-DOTA-1-Nal3-octreotide177Lu-DOTA-Nal(3)-octreotide177Lu-DOTA-Nal3-octreotide177Lu-DOTANOClutetium (177Lu) DOTA-NOClutetium (177Lu) DOTANOClutetium Lu 177 DOTA-NOClutetium Lu 177 DOTANOClutetium-177-DOTA-NOClutetium177-DOTA-NOClutetium 177-DOTA-NOC